Seed Health

What Happened

Seed Health is a rare profitable biotech in this space — its DS-01 daily synbiotic became Target's fastest-growing probiotics brand, generating an estimated $200M in 2024 revenue, which it is now plowing into CODA, an AI-driven computational biology platform for microbiome research.

Why It Matters

Actual profitability, with an estimated $200M in 2024 revenue from one flagship product, is rare in this space — most microbiome-focused companies are still burning venture capital waiting for the science to commercialize.

Rare in this space: a company funding its research with its own profits.

FET's Takeaway

Reinvesting consumer-product profits into CODA, a computational biology research platform, is a sequencing most biotech startups can't afford — funding real research from commercial cash flow instead of the other way around.